Erratum: Corrigendum: PAI-1 mediates the antiangiogenic and profibrinolytic effects of 16K prolactin

Bajou, Khalid; Herkenne, Stéphanie; Thijssen, Victor L.; D’Amico, Salvino; Nguyen, Ngoc-Quynh-Nhu; Bouché, Ann; Tabruyn, Sébastien P.; Srahna, Mohammed; Carabin, Jean-Yves; Nivelles, Olivier; Paques, Cécile; Cornelissen, Ivo; Lion, Michelle; Noël, Agnès; Gils, Ann; Vinckier, Stefan; Declerck, Paul; Dewerchin, Mieke; Martial, Joseph; Carmeliet, Peter; Struman, Ingrid

doi:10.1038/nm0515-537a

Cited by 2 publications

(2 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…16-kDa Prolactin fragment also triggers endothelial and cardiomyocyte damage. It induces endothelial cells to package microRNA specifically, miR-146a into exosomes, which are then secreted and taken up by the cardiomyocytes, thereby promoting cardiomyocyte apoptosis by suppressing the neuregulin/ErbB pathway [ 17 , 18 ].…”

Section: Methodsmentioning

confidence: 99%

Review of Randomized Controlled Trials in Patients with Peripartum Cardiomyopathy

Mujkanovic

Qayyum

2023

CCR

View full text Add to dashboard Cite

Introduction: Peripartum cardiomyopathy (PPCM) is a rare but potentially life-threatening disease, defined as idiopathic cardiomyopathy occurring towards the end of pregnancy or in the months following delivery, abortion or miscarriage. We aim to raise awareness of this condition and give an overview of current knowledge as well as an insight and comparison of clinical trials focusing on randomized controlled trials. Material and methods: Systematic literature searches were conducted using PubMed up to December 2021. Studies published involving clinical trials and interventions in women with PPCM after 1970 were selected. Results: Randomized controlled trials have shown that addition of Bromocriptine to standardized heart failure therapy improves outcome in terms of recovery of left ventricular ejection fraction (LVEF), symptoms and death. Bromocriptine 2.5 mg twice daily for two weeks followed by 2.5 mg once daily for six weeks had the best trend anAddition of Levosimendan to standardized heart failure therapy had no effect, whereas addition of Selenium had an improvement in heart failure symptoms but did not reduce risk in terms of unrecovered LVEF or death. One prospective study showed a potential usage of TNF-alfa inhibitors, but was never tried in a randomized clinical trial.d outcome. Conclusion: PPCM is a rare and potentially fatal disease. New insights in pathophysiology, genetics and clinical studies, particularly randomized controlled trials have shown that addition of Bromocriptine has a beneficial effect in terms of improved LVEF and death. However, some clinical studies have shown promising results using anti-inflammatory pharmacological agents with an improvement in LVEF. We suggest that targeting an anti-inflammatory route may prove beneficial in patients with PPCM. However, further research is highly warranted.

show abstract

Section: Methodsmentioning

confidence: 99%

Review of Randomized Controlled Trials in Patients with Peripartum Cardiomyopathy

Mujkanovic

Qayyum

2023

CCR

View full text Add to dashboard Cite

show abstract

“…As such, the vasculotoxic hormonal changes that occur during and after parturition act as a trigger for PPCM. Indeed, several studies have demonstrated that PPCM is triggered by the rapidly changing environment of late gestation thus inducing vasculopathy in susceptible women ( 13 , 27 , 28 ). This is supported by the fact that hormones that likely trigger PPCM (PRL and sFlt1) are mostly at their peak in late pregnancy and postpartum.…”

Section: Cardiac Mechanical Stress During Pregnancymentioning

confidence: 99%

Heat Shock Proteins: Potential Modulators and Candidate Biomarkers of Peripartum Cardiomyopathy

Chakafana

Spracklen

Kamuli

et al. 2021

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

Peripartum cardiomyopathy (PPCM) is a potentially life-threatening condition in which heart failure and systolic dysfunction occur late in pregnancy or within months following delivery. To date, no reliable biomarkers or therapeutic interventions for the condition exist, thus necessitating an urgent need for identification of novel PPCM drug targets and candidate biomarkers. Leads for novel treatments and biomarkers are therefore being investigated worldwide. Pregnancy is generally accompanied by dramatic hemodynamic changes, including a reduced afterload and a 50% increase in cardiac output. These increased cardiac stresses during pregnancy potentially impair protein folding processes within the cardiac tissue. The accumulation of misfolded proteins results in increased toxicity and cardiac insults that trigger heart failure. Under stress conditions, molecular chaperones such as heat shock proteins (Hsps) play crucial roles in maintaining cellular proteostasis. Here, we critically assess the potential role of Hsps in PPCM. We further predict specific associations between the Hsp types Hsp70, Hsp90 and small Hsps with several proteins implicated in PPCM pathophysiology. Furthermore, we explore the possibility of select Hsps as novel candidate PPCM biomarkers and drug targets. A better understanding of how these Hsps modulate PPCM pathogenesis holds promise in improving treatment, prognosis and management of the condition, and possibly other forms of acute heart failure.

show abstract

Erratum: Corrigendum: PAI-1 mediates the antiangiogenic and profibrinolytic effects of 16K prolactin

Cited by 2 publications

References 1 publication

Review of Randomized Controlled Trials in Patients with Peripartum Cardiomyopathy

Review of Randomized Controlled Trials in Patients with Peripartum Cardiomyopathy

Heat Shock Proteins: Potential Modulators and Candidate Biomarkers of Peripartum Cardiomyopathy

Contact Info

Product

Resources

About